{"genes":["BRAF","NRAS","NRAS"],"publicationTypes":["Journal Article"],"abstract":"Melanoma harbors recurrent oncogenic driver mutations in BRAF and NRAS, but these mutations\u0027 impact on immunotherapy outcomes is unclear. We assessed 229Â patients treated with immunotherapy, and found that clinical outcomes were largely superior in those with NRAS mutations. Herein, we discuss our findings and their implications for melanoma therapeutics. ","title":"Melanoma driver mutations and immune therapy.","pubmedId":"27467925"}